Clinical Trial Update: SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating sofosbuvir-based regimens with ribavirin for 16 or 24 weeks and with pegylated interferon for 12 weeks in adults with genotype 2 or 3 c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Pegylated interferon (pegylated interferon alfa)
• Ribavirin (ribavirin)
• Sovaldi (Sofosbuvir)

Snippet

Sponsor: Gilead Sciences | Conditions: Hepatitis C | Phase 3 | Status: COMPLETED | Results posted: 2016-02-05